Show simple item record

dc.contributor.authorTargeted Alpha Therapy Working Group
dc.contributor.authorParker, C
dc.contributor.authorLewington, V
dc.contributor.authorShore, N
dc.contributor.authorKratochwil, C
dc.contributor.authorLevy, M
dc.contributor.authorLindén, O
dc.contributor.authorNoordzij, W
dc.contributor.authorPark, J
dc.contributor.authorSaad, F
dc.date.accessioned2018-11-20T11:14:28Z
dc.date.issued2018-12
dc.identifier.citationJAMA oncology, 2018, 4 (12), pp. 1765 - 1772
dc.identifier.issn2374-2437
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2948
dc.identifier.eissn2374-2445
dc.identifier.doi10.1001/jamaoncol.2018.4044
dc.description.abstractImportance Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells while minimizing systemic toxic effects and may lead to additional treatment options for many cancer types.Observations Theoretically, the high-energy emission of short-range alpha particles causes complex double-stranded DNA breaks, eliciting cell death. No known resistance mechanism to alpha particles has been reported or scientifically established. The short-range emission of alpha particle radiation confines its cytotoxic effect to cancerous lesions and the surrounding tumor microenvironment while limiting toxic effects to noncancerous tissues. The high level of radiobiological effectiveness of alpha particles, in comparison with beta emissions, requires fewer particle tracks to induce cell death. Clinically effective alpha particle-emitting isotopes for cancer therapy should have a short half-life, which will limit long-term radiation exposure and allow for the production, preparation, and administration of these isotopes for clinical use and application. Radium 223 dichloride is the first-in-class, commercially available targeted alpha therapy approved for the treatment of patients with metastatic castration-resistant prostate cancer with bone metastases. Given the established overall survival benefit conferred by radium 223 for patients with metastatic castration-resistant prostate cancer, several other targeted alpha therapies are being investigated in clinical trials across many tumor types.Conclusions and relevance Targeted alpha therapy represents an emerging treatment approach and provides for the possibility to bypass mechanisms of acquired resistance in selected tumors. In addition, developing novel radionuclide conjugation strategies may overcome targeting limitations. So far, the clinical success of radium 223 has demonstrated the proof of concept for targeted alpha therapy, and future studies may lead to additional treatment options for many cancer types.
dc.formatPrint
dc.format.extent1765 - 1772
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectTargeted Alpha Therapy Working Group
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectBone Neoplasms
dc.subjectRadium
dc.subjectRadioisotopes
dc.subjectRadiotherapy
dc.subjectTherapies, Investigational
dc.subjectAlpha Particles
dc.subjectMale
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.titleTargeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
dc.typeJournal Article
rioxxterms.versionofrecord10.1001/jamaoncol.2018.4044
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJAMA oncology
pubs.issue12
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume4
pubs.embargo.termsNot known
dc.contributor.icrauthorParker, Chrisen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record